Drug Trial Radar · NCT04926701
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Jun 11, 2021
Primary completion
Mar 22, 2022
Study completion Mar 22, 2022
Sponsor
- Lead sponsor
- Enterprise Therapeutics LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of inhaled ETD001in healthy male and female subjects.
Conditions
- Cystic Fibrosis
Interventions
ETD001 single doseDrug
Single ascending doses of inhaled ETD001
Placebo single doseDrug
Single doses of inhaled placebo
ETD001 multiple twice daily dosesDrug
Ascending doses of inhaled ETD001 administered twice daily
Placebo multiple twice daily dosesDrug
Doses of inhaled placebo administered twice daily
ETD001 multiple once daily dosesDrug
Doses of inhaled ETD001 administered once daily
Placebo multiple once daily dosesDrug
Doses of inhaled placebo administered once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting one or more treatment emergent adverse event (TEAE)Time frame: Baseline to Week 8
- Number of participants who discontinue due to an adverse event (AE)Time frame: Baseline to Week 8
- Number of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at least once post doseTime frame: Baseline to Week 8
- Number of participants who meet the markedly abnormal criteria for vital signs assessments at least once post doseTime frame: Baseline to Week 8
- Number of participants who meet the markedly abnormal criteria for laboratory assessments at least once post doseTime frame: Baseline to Week 8
- Number of participants who meet the markedly abnormal criteria for spirometry assessments at least once post doseTime frame: Baseline to Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Medicines Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.